Sanofi, Recordati
Recordati buys rights to rare immune disorder drug from Sanofi for $825 million
(Reuters) -Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat cold agglutinin disease (CAD), a rare autoimmune disorder, for $825 million,
Sanofi Offloads Rare Autoimmune Drug to Recordati in Potential $1B Deal
Under the deal announced Friday, the Italian pharma will make an upfront payment of $825 million to Sanofi for global rights to a biologic for the treatment of cold agglutinin disease, with milestone payments of up to $250 million.
In sustained rare disease push, Recordati lays out $825M upfront to acquire Sanofi's CAD drug Enjaymo
As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. | Recordati is floating $825 million upfront—plus another $250 million in potential commercial milestones—to get its hands on the global rights to Sanofi’s rare disease biologic Enjaymo.
Recordati to acquire worldwide rights to Sanofi’s antibody Enjaymo
Recordati has reached an agreement with Sanofi for acquiring the worldwide rights to Enjaymo, the only approved treatment specifically targeting cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder.
Sanofi’s rare disease drug finds yet another home
Having already been on a winding journey, Enjaymo, which Sanofi acquired through a 2018 buyout of Bioverativ, is now headed to Recordati as part of a deal announced Friday.
Sanofi Sells Global Rights To Rare Autoimmune Drug Enjaymo For $825M Upfront To Italian Firm Recordati
Italian pharma company Recordati S.p.A agreed to acquire the global rights to Enjaymo (sutimlimab) from Sanofi SA (NASDAQ:SNY) for $825 million as an upfront payment and additional commercial milestone payments of up to $250 million.
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE
Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic
FiercePharma11d
Sanofi, Regeneron look to seize major opportunity with Dupixent's COPD approval
After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...
Sanofi Healthcare Bidders Revising Offers Over Talc Concerns
Bidders for Sanofi’s consumer healthcare unit are revising their offers in part to address concerns around potential ...
GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report
The U.S. government has granted $72 million to European pharma giants GSK Plc (NYSE:GSK), Sanofi SA (NASDAQ:SNY) and ...
MedCity News9d
Sanofi and Regeneron Biologic Drug Dupixent Notches a New FDA Approval in COPD
The blockbuster Sanofi and Regeneron Pharmaceuticals drug Dupixent, already commercialized in several skin and lung disorders, has expanded its FDA-approval to chronic obstructive pulmonary ...
Zacks Industry Outlook Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer
Among the large drugmakers, Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer are worth retaining in one’s portfolio.
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their drug to treat chronic obstructive pulmonary ...
Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff
Sanofi SA (NASDAQ:SNY) announced its plans to spin off its consumer healthcare business as the French pharmaceutical company ...
FiercePharma1d
Dupixent takes pharma DTC top spot as Pfizer's COVID drug Paxlovid makes a comeback
AbbVie’s immunology duo Skyrizi and Rinvoq is, in a rare blip this year, not leading the pharma DTC monthly rankings as ...